Oppenheimer Hikes Ascendis Pharma Price Target on Strong Yorvipath Demand Outlook
Ascendis Pharma A/S (NASDAQ:ASND) is one of billionaire Stan Druckenmiller’s top stock picks with huge upside potential.
Ascendis Pharma A/S (ASND)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | RA Capital Management Peter Kolchinsky | 10,281,496 | $1,602,473,967 | +2% | 26.76% |
| 2. | VenBio Select Advisor Kurt Von Emster | 5,218,000 | $813,277,480 | +3% | 12.69% |
| 3. | Citadel Investment Group Ken Griffin | 1,125,183 | $175,371,023 | +26% | 0.03% |
| 4. | Point72 Asset Management Steve Cohen | 569,146 | $88,707,165 | +14% | 0.2% |
| 5. | Polar Capital Brian Ashford-Russell And Tim Woolley | 525,000 | $81,826,500 | +75% | 0.5% |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 482,000 | $602,611 | 0.08% | |
| 2. | 42 | $7,249 | 0.01% |
News See All
Billionaire Stan Druckenmiller's 10 Stock Picks with Huge Upside Potential
Stanley Druckenmiller, an American billionaire investor, is the founder of Duquesne Capital.
Ascendis Pharma (ASND) Rated as a Hold at Cannacord Genuity on Growth Hormone Prospects
Ascendis Pharma A/S (NASDAQ:ASND) is among the 12 best healthcare stocks to buy now. On June 10, Canaccord Genuity reiterated a Hold rating on the stock and an $84 price target.
12 Best Healthcare Stocks to Buy Now
Healthcare companies in the US are facing policy headwinds under President Donald Trump's Administration.
BofA Hikes Ascendis Pharma Price Target to $216 Affirms Buy Rating
Ascendis Pharma A/S (NASDAQ:ASND) is one of the best 52-week high stocks to buy, according to analysts.
10 Best 52-Week High Stocks to Buy According to Analysts
Volatility in the equity markets under President Donald Trump has already hit record highs. Amid the heightened volatility, US equities have also bounced back on optimism about US-China trade negotiations...
TransCon® hGH Boosts TransCon® CNP Results in Kids with Achondroplasia by Week 26
Ascendis Pharma A/S (NASDAQ:ASND) is among the 13 Biotech Stocks with Huge Upside Potential.
13 Biotech Stocks with Huge Upside Potential
The FDA Commissioner Marty Makary stated the FDA will reach its 2025 drug approval targets despite severe workforce reductions.
12 Best Growth Stocks to Buy and Hold for the Long Term
The market closed last week mostly lower, however, the S&P 500 has been up more than 7% since April 11, indicating a returning positive sentiment.
Launch of New Drug Lifted Ascendis Pharma A/S (ASND) in Q1
Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here.
Billionaire Hedge Funds
